Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

Dannon, Pinhas N.; Sasson, Yehuda; Hirschmann, Shmuel; Iancu, Iulian; Grunhaus, Leon; Zohar, Joseph

doi:10.1016/s0924-977x(00)00065-1

Cited by 98 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study suggests that SSRIs combined with low doses of the 5-HT 1A receptor antagonist may result in augmentative therapy for treatment of OCD, as in depression (Blier and Bergeron, 1998;Artigas et al, 2001). In accordance with this idea, Dannon et al (2000) demonstrated that pindolol, a 5-HT 1A /b-adrenergic antagonist, may augment the therapeutic effect of paroxetine, an SSRI, in treatment-resistant OCD patients.…”

Section: Discussionsupporting

confidence: 77%

Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice

Harasawa

Ago

Itoh

et al. 2006

Behavioural Pharmacology

View full text Add to dashboard Cite

This study examined the roles of presynaptic and postsynaptic serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice. The effect of fluvoxamine was attenuated by the serotonin type 1A receptor antagonist WAY100635 at 1 mg/kg, while it was enhanced by the antagonist at 0.1 mg/kg. Fluvoxamine (30 mg/kg) and WAY100635 (0.1 and 1 mg/kg) did not affect spontaneous locomotor activity. These results suggest that the effect of fluvoxamine is mediated by postsynaptic serotonin type 1A receptors and it is enhanced by an inhibition of presynaptic serotonin type 1A receptors.

show abstract

Section: Discussionsupporting

confidence: 77%

Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice

Harasawa

Ago

Itoh

et al. 2006

Behavioural Pharmacology

View full text Add to dashboard Cite

show abstract

“…In relation to anxiety, beta blockers have been used to treat performance anxiety [40] and to enhance the effect of selective serotonin reuptake inhibitors (SSRI) in panic disorder [41] and obsessive-compulsive disorder [42]. We did not find evidence for a negative association with anxiety symptoms in our study of hypertensive subjects, which is in agreement with the bulk of previous well-designed studies.…”

Section: Associations Between Specific Drug Classes and Depression Ansupporting

confidence: 91%

Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. The HUNT study, Norway

et al. 2011

View full text Add to dashboard Cite

Antihypertensive drugs have been suggested to modulate symptoms of depression and anxiety. It is disputed whether this is due to the hypertension per se, its treatment, or both. The aim of this study was to investigate these associations in a large population sample. 55,472 participants in the Nord-Trøndelag Health Study (HUNT 2, 1995-1997), Norway, who completed the Hospital Anxiety and Depression rating Scale, were divided into 3 groups according to their diastolic blood pressure and antihypertensive treatment status. A cut-off of ≥90 mmHg diastolic blood pressure was used to identify hypertensive status. Differences in anxiety and depression symptom levels in untreated and treated hypertensives (all treatments) versus the normotensive reference group were explained by differences in age and gender distribution in the three groups in this study. However, the receipt of two or more antihypertensive drugs was associated with depressive symptoms alone (OR = 1.40, 95% CI = 1.03-1.90), but not with symptoms of anxiety (OR = 1.14, 95% CI = 0.83-1.57) or mixed anxiety and depression (OR = 1.19, 95% CI = 0.82-1.72) in the fully adjusted model, compared to untreated hypertension. Antihypertensive monotherapy (all agents) nor any single antihypertensive drug class were associated with symptoms of depression, anxiety, or mixed anxiety and depression. There may be a positive association between multi antihypertensive drug use and symptoms of depression, whereas this was not found in persons with symptoms of anxiety or mixed anxiety and depression. This might reflect poor antihypertensive treatment adherence leading to polypharmacy, or other unfavorable health behaviors in people with symptoms of pure depression.

show abstract

“…Pindolol, a β-adrenergic blocker with putative antagonistic action at presynaptic 5HT 1A receptor has shown efficacy (at a dose of 2.5 mg three-times daily) as an augmenting agent to paroxetine in a 6-week, double-blind, placebo-controlled trial in OCD patients (n = 23) resistant to treatment with at least two SSRIs [74], but not in another RCT [75].…”

Section: β-Blockersmentioning

confidence: 99%

Augmentation strategies in obsessive–compulsive disorder

Arumugham

Reddy

2013

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

Cited by 98 publications

References 24 publications

Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice

Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice

Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. The HUNT study, Norway

Augmentation strategies in obsessive–compulsive disorder

Contact Info

Product

Resources

About